Nuzenio

Danon Disease

Danon Disease news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

topic 6 latest news signals 6 publisher sources 100/100 entity strength

Latest news

Rocket points to Danon gene therapy’s safety after Phase II protocol change - Clinical Trials ArenaClinical Trials Arena · Tue, 04 Aug 2026 10:29:25 GMTRocket Pharmaceuticals Reports Positive Safety Update for RP-A501 Under Modified Phase 2 Protocol in Danon Disease - BioPharm InternationalBioPharm International · Mon, 03 Aug 2026 17:07:07 GMTRocket Pharmaceuticals Touts Positive Early Safety Data from Revised Genetic Therapy Trial - BenzingaBenzinga · Mon, 03 Aug 2026 16:03:07 GMTRocket Pharmaceuticals (RCKT) Reports Positive Safety Signals in Phase 2 Trial for Danon Disease - GuruFocusGuruFocus · Mon, 03 Aug 2026 13:01:56 GMTRocket Pharmaceuticals Announces Positive Clinical Safety Update from Initial Three Patients Treated with RP-A501 Under Modified Phase 2 Protocol for Danon Disease - Business WireBusiness Wire · Mon, 03 Aug 2026 11:00:00 GMTRocket Pharmaceuticals Provides Positive Clinical Safety Update from Initial Three Patients Treated with Rp-A501 Under Modified Phase 2 Protocol for Danon Disease - marketscreener.commarketscreener.com · Mon, 03 Aug 2026 11:00:00 GMT

Timeline

Tue, 04 Aug 2026 10:29:25 GMTRocket points to Danon gene therapy’s safety after Phase II protocol change - Clinical Trials Arena
Mon, 03 Aug 2026 17:07:07 GMTRocket Pharmaceuticals Reports Positive Safety Update for RP-A501 Under Modified Phase 2 Protocol in Danon Disease - BioPharm International
Mon, 03 Aug 2026 16:03:07 GMTRocket Pharmaceuticals Touts Positive Early Safety Data from Revised Genetic Therapy Trial - Benzinga
Mon, 03 Aug 2026 13:01:56 GMTRocket Pharmaceuticals (RCKT) Reports Positive Safety Signals in Phase 2 Trial for Danon Disease - GuruFocus
Mon, 03 Aug 2026 11:00:00 GMTRocket Pharmaceuticals Announces Positive Clinical Safety Update from Initial Three Patients Treated with RP-A501 Under Modified Phase 2 Protocol for Danon Disease - Business Wire
Mon, 03 Aug 2026 11:00:00 GMTRocket Pharmaceuticals Provides Positive Clinical Safety Update from Initial Three Patients Treated with Rp-A501 Under Modified Phase 2 Protocol for Danon Disease - marketscreener.com

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Danon Disease.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

6 distinct publisher/source names are currently connected to this entity page.